Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

NATerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

August 22, 2022

Study Completion Date

April 13, 2023

Conditions
COVIDCorona Virus InfectionRespiratory FailureRespiratory Distress Syndrome, AdultARDS, HumanSARS (Severe Acute Respiratory Syndrome)
Interventions
DEVICE

gammaCore® Sapphire (non-invasive vagus nerve stimulator)

"Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.~For acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment."

OTHER

Standard of care therapies

Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms

Trial Locations (2)

15212

AHN Allegheny General Hospital, Pittsburgh

15224

AHN West Penn Hospital, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ElectroCore INC

INDUSTRY

lead

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

OTHER